## **Xifaxan (rifaximin) Prior Authorization Request Form**

**Caterpillar Prescription Drug Benefit** 

Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: \_\_\_\_\_\_ MEMBER'S FIRST NAME: \_\_\_\_\_

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

MEMBER INFORMATION	
LAST NAME:	FIRST NAME:
PHONE NUMBER:	DATE OF BIRTH:
STREET ADDRESS:	I
CITY:	STATE: ZIP CODE:
PATIENT INSURANCE ID NUMBER:	I

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: PRIMETHERAPEUTICS.COM/NOPP

MALE FEMALE HEIGHT (IN/CM): \_\_\_\_\_ WEIGHT (LB/KG): \_\_\_\_\_ ALLERGIES: \_\_\_\_\_

#### PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE): \_\_\_\_\_\_

AUTHORIZED REPRESENTATIVE'S PHONE NUMBER:

PRESCRIBER INFORMATION				
LAST NAME:	FIRST NAME:			
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:			
NPI NUMBER:	DEA NUMBER:			
PHONE NUMBER:	FAX NUMBER:			
STREET ADDRESS:				
CITY:	STATE: ZIP CODE:			
REQUESTOR (if different than prescriber):	OFFICE CONTACT PERSON:			

MEDICATION OR MEDICAL DISPENSING INFORMATION					
MEDICATION NAME:					
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:		
NEW THERAPY		IF RENEWAL: DATE THERAPY INITIATED:			
DURATION OF THERAPY (SPECIFIC DATES):					
Continued on mouth name					

*Continued on next page* 



# Xifaxan (rifaximin) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:				
1. HAS THE PATIENT TRIED ANY OTHER	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NO			
MEDICATION/THERAPY (SPECIFY	<b>DURATION OF THERAPY</b> (SPECIFY	RESPONSE/REASON FOR			
DRUG NAME AND DOSAGE):	DATES):	FAILURE/ALLERGY:			
2. LIST DIAGNOSES:		ICD-10:			
C. difficile colitis					
<ul> <li>Hepatic encephalopathy</li> <li>Diarrhea-predominant Irritable bowel system</li> </ul>	ndrome(IBS-D)				
<ul> <li>Intestinal bacterial overgrowth(IBO)</li> </ul>					
□ Travelers' diarrhea					
□ Other diagnosis:ICD-	10				
	: PLEASE PROVIDE ALL RELEVANT CLINIC	AL INFORMATION TO SUPPORT A			
PRIOR AUTHORIZATION.					
<u>C. difficile colitis:</u>					
was the diagnosis confirmed by the pa	atient's lab results showing that the tox	In is present? 🗆 Yes 🗆 No			
Hepatic encephalopathy: Has the patient failed a trial of lactulose?					
Will Xifaxan be used in combination w	rith lactulose? 🗆 Yes 🗆 No				
Does the patient have a medical contr	aindication to lactulose?  □ Yes □ No				
If yes to the above, please submit doc					
Irritable bowel syndrome with diarrhea (IBS-D):					
Has the patient been previously treated with Xifaxan for IBS-D in the past? 🗆 Yes 🗆 No					
In Vifeware have and fourther two attracts of intersting the start of the second to (100)2. Also, Also,					
Is Xifaxan being used for the treatment of intestinal bacterial overgrowth (IBO)? $\Box$ Yes $\Box$ No					
Are there any other comments, diagno	oses, symptoms, medications tried or fa	iled, and/or any other information the			
physician feels is important to this rev	iew?	•			
Please note: Not all drugs/diagnoses and	re covered on all plans. This request may	be denied unless all required			
information is received.					



# Xifaxan (rifaximin) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit

Phone: 877-228-7909 Fax: 800-424-7640

#### MEMBER'S LAST NAME: \_\_\_\_

#### MEMBER'S FIRST NAME: \_\_\_\_\_

**ATTESTATION:** I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

\_\_\_\_\_

Prescriber Signature or Electronic I.D. Verification:

Date:

**CONFIDENTIALITY NOTICE:** The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

### FAX THIS FORM TO: 800-424-7640

### MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program

Attn: CP - 4201 P.O. Box 64811 St. Paul, MN 55164-0811